Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viet Nam Pharmaceutical - JSCHSTC:DVN 80 Return-on-Tangible-Asset is 7.50% as of Mar. 2026, which is 102% above its 10-year median of 3.72. GuruFocus rates HSTC:DVN with a GF Score™ of 80/100 and a GF Value™ of ₫22,082.23 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,009 Drug Manufacturers companies, Viet Nam Pharmaceutical - JSC ranks better than 77.4% on this metric.
The historical rank and industry rank for Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Asset or its related term are showing as below:
HSTC:DVN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.48 Med: 3.72 Max: 10.67
Current: 9.78
During the past 7 years, Viet Nam Pharmaceutical - JSC's highest Return-on-Tangible-Asset was 10.67%. The lowest was 1.48%. And the median was 3.72%.
HSTC:DVN's Return-on-Tangible-Asset is ranked better than 77.4% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs HSTC:DVN: 9.78
Viet Nam Pharmaceutical - JSC (HSTC:DVN) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Viet Nam Pharmaceutical - JSC Return-on-Tangible-Asset Related Terms
Viet Nam Pharmaceutical - JSC Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viet Nam Pharmaceutical - JSC Return-on-Tangible-Asset Chart
HSTC:DVN vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viet Nam Pharmaceutical - JSC Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 7.50% mean?
Viet Nam Pharmaceutical - JSC (HSTC:DVN) has a Return-on-Tangible-Asset of 7.50% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Viet Nam Pharmaceutical - JSC and its competitors. This is 102% above median its historical median of 3.72. Over the past decade, Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Asset has ranged from 1.48 to 10.67. According to the industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #228 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 22.6%.
Is Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Asset too high?
Viet Nam Pharmaceutical - JSC's current Return-on-Tangible-Asset of 7.50% is 102% above median its 10-year median of 3.72. Over the past 10 years, this metric has ranged from a low of 1.48 to a high of 10.67. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.13. Viet Nam Pharmaceutical - JSC's value of 7.50% is 139.6% above this industry median. Based on the distribution chart, Viet Nam Pharmaceutical - JSC ranks #228 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Viet Nam Pharmaceutical - JSC has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #228 out of 1009 companies for Return-on-Tangible-Asset. This places Viet Nam Pharmaceutical - JSC in the top 23% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.13. Viet Nam Pharmaceutical - JSC's value of 7.50% is 139.6% above this benchmark. Historically, Viet Nam Pharmaceutical - JSC's own Return-on-Tangible-Asset has ranged from 1.48 to 10.67 over the past decade. While the company's 10-year median is 3.72 vs. the industry median of 3.13, Viet Nam Pharmaceutical - JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.13, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viet Nam Pharmaceutical - JSC's current Return-on-Tangible-Asset of 7.50% is 139.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Viet Nam Pharmaceutical - JSC and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viet Nam Pharmaceutical - JSC's current Return-on-Tangible-Asset is 7.50%, which is 102% above median its own 10-year median of 3.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viet Nam Pharmaceutical - JSC stock overvalued right now?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC (HSTC:DVN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫22,082.23, compared to a current price of ₫18,700.00 — trading 15.3% below its estimated fair value. The current Return-on-Tangible-Asset is 7.50%, which is 102% above median its 10-year median of 3.72 and 139.6% above the Drug Manufacturers industry median of 3.13. Viet Nam Pharmaceutical - JSC's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Viet Nam Pharmaceutical - JSC (HSTC:DVN), the current Return-on-Tangible-Asset is 7.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viet Nam Pharmaceutical - JSC (HSTC:DVN) Overvalued in 2026?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC stock appears to be undervalued.
The current stock price of ₫18,700.00 is trading 15.3% below its estimated GF Value™ of ₫22,082.23.
GuruFocus considers Viet Nam Pharmaceutical - JSC to be Modestly Undervalued.
Key valuation signals for HSTC:DVN:
Return-on-Tangible-Asset: 7.50% (102% above median its 10-year median of 3.72)
GF Value™: ₫22,082.23 vs. price of ₫18,700.00 (15.3% below fair value)
Industry Position: 139.6% above the Drug Manufacturers median (#228 of 1009)
No single metric tells the full story. See the HSTC:DVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viet Nam Pharmaceutical Corp - JSC is engaged in the manufacturing of drugs. The company provides testing services for drugs and medicinal ingredients.
80GF Score
Get the complete analysis for HSTC:DVN
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:DVN has been successfully added to your 
